Clinical researchers provided more details of safety trials involvingtreatment of traumatic brain injury with Cerestat (CNS 1102), aneuroprotective agent being developed by Cambridge NeuroScienceInc. The data were presented at the annual Scientific Meeting ofNeuroanaethesia Society of Great Britain and Ireland this pastweekend.Researchers said the drug was safe in humans up to the doses expectedto provide cerebral protection, and that it appears to lower intracranialpressure (ICP) and temperature.Twenty-five patients who had suffered severe head injury in theprevious 72 hours received a bolus infusion of Cerestat followed by aninfusion of the drug for four hours in an open label study. Mean ICPand temperature fell during administration of the drug and returned tobaseline within 12 hours.Efficacy trials in the patient population are planned later this year, theCambridge, Mass., company said. Cerestat, an NMDA ion-channelblocker, acts to prevent nerve cell death and brain damage bypreventing excessive entry of calcium into nerve cells.Sixty-five people, including placebos, have been treated in a separatePhase I/II trial testing Cerestat in stroke patients, at eight centers in theU.S. _ Jim Shrine
(c) 1997 American Health Consultants. All rights reserved.